Compare
Bio-Techne Corp vs Novavax Inc vs Halozyme Therapeutics, Inc. vs Moderna, Inc.
| Latest fiscal year | Bio-Techne Corp TECH | Novavax Inc NVAX | Halozyme Therapeutics, Inc. HALO | Moderna, Inc. MRNA |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.22B | $1.12B | $1.40B | $1.94B |
| Revenue growth (YoY) | -0.4% | +64.7% | +37.6% | -39.9% |
| Gross margin | 65.8% | 93.5% (computed) | 83.6% (computed) | 55.3% (computed) |
| Operating margin | 20.7% | 40.3% | 33.6% | -158.1% |
| Net margin | 15.0% | 39.2% | 22.7% | -145.2% |
| Net income | $181.86M | $440.30M | $316.89M | -$2.82B |
| EPS (Diluted) | $1.16 | $2.58 | $2.56 | -$7.26 |
| Operating cash flow | $292.07M | -$244.63M | $651.56M | -$1.87B |
| Free cash flow | $263.22M | n/a | $644.59M | -$2.06B |
| Cash & equivalents | $264.71M | $240.63M | $133.82M | $2.60B |
| Total assets | $2.59B | $1.18B | $2.53B | $12.34B |
| Total liabilities | n/a | $1.30B | $2.48B | $3.69B |
| Shareholders' equity | $2.11B | -$127.75M | $48.81M | $8.65B |
| Return on year-end equity | 8.6% | n/a | 649.2% | -32.6% |
| Shares outstanding | 156.10M | 162.58M | 117.78M | 394.00M |
Revenue, most recent five fiscal years
| Fiscal year | Bio-Techne Corp | Novavax Inc | Halozyme Therapeutics, Inc. | Moderna, Inc. |
|---|---|---|---|---|
| Latest | $1.22B Ended 2026-06-30 | $1.12B Ended 2025-12-31 | $1.40B Ended 2025-12-31 | $1.94B Ended 2025-12-31 |
| 1 year earlier | $1.22B Ended 2025-06-30 | $682.16M Ended 2024-12-31 | $1.02B Ended 2024-12-31 | $3.24B Ended 2024-12-31 |
| 2 years earlier | $1.16B Ended 2024-06-30 | $983.71M Ended 2023-12-31 | $829.25M Ended 2023-12-31 | $6.85B Ended 2023-12-31 |
| 3 years earlier | $1.14B Ended 2023-06-30 | $1.98B Ended 2022-12-31 | $660.12M Ended 2022-12-31 | $19.26B Ended 2022-12-31 |
| 4 years earlier | $1.11B Ended 2022-06-30 | $1.15B Ended 2021-12-31 | $443.31M Ended 2021-12-31 | $18.47B Ended 2021-12-31 |